November 2026 biotech catalysts

Name: Bio Catalyst Calendar — source-anchored biotech/pharma catalyst dates
Creator: Bio Catalyst Calendar
License: https://www.usa.gov/government-works

62 verified catalyst event(s) dated in November 2026, each linked to its official source. Verified as of 2026-11-04.

Date	Event	Company	Drug	Official source & verification
2026-11-05 in 1d ESTIMATED	READOUT Pediatric Long-Term Follow-up and Rollover Study Phase 4 · Diffuse Astrocytoma, Anaplastic Astrocytoma	NVS NOVARTIS AG	dabrafenib, trametinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-05 in 1d ESTIMATED	READOUT Rollover Study to Provide Continued Treatment for Participants With B-Cell Malig Phase 2 · B-Cell Malignancies	INCY INCYTE CORP	Parsaclisib, parsaclisib + itacitinib, p	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-05 in 1d ESTIMATED	READOUT A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metast Phase 1/2 · Prostate Cancer	AZN ASTRAZENECA PLC	AZD9750, AZD5305	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-09 in 5d ESTIMATED	READOUT A Platform Study of Novel Immunotherapy Combinations in Participants With Previo Phase 2 · Lung Cancer, Non-Small Cell	GlaxoSmithKline	Pembrolizumab, Dostarlimab, Belrestotug,	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-11 in 7d ESTIMATED	READOUT PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metast Phase 2 · Cervical Cancer, HPV-Related Carcinoma	PGEN PRECIGEN, INC.	PRGN-2009 plus Pembrolizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-12 in 8d ESTIMATED	READOUT A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In Peop Phase 2 · Atopic Dermatitis	PFE PFIZER INC	PF-07275315, PF-07264660	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-13 in 9d ESTIMATED	READOUT A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination Wi Phase 1/2 · Advanced Solid Tumors	REGN REGENERON PHARMACEUTICALS, I	REGN7075, Cemiplimab, Platinum-based dou	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-13 in 9d ESTIMATED	READOUT A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compar Phase 3 · Breast Cancer	Hoffmann-La Roche	Inavolisib, Fulvestrant, Alpelisib, Bupr	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-13 in 9d ESTIMATED	READOUT Study of Olatorepatide in Adult Participants Living With Overweight or Obesity i Phase 2 · Overweight or Obesity	REGN REGENERON PHARMACEUTICALS, I	Olatorepatide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-14 in 10d ESTIMATED	READOUT A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Di Phase 3 · Type 2 Diabetes Mellitus (T2DM)	BrightGene Bio-Medical Technology	Drug: 5 mg BGM0504 Administered SC, Drug	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-14 in 10d ESTIMATED	READOUT A Study of BGM0504 in Participants With Type 2 Diabetes Phase 3 · Type 2 Diabetes Mellitus (T2DM)	BrightGene Bio-Medical Technology	Drug: 5 mg BGM0504 Administered SC, Drug	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-15 in 11d ESTIMATED	READOUT Efficacy of M640 in Acute Lumbosacral Musculoskeletal Conditions. Phase 4 · Sciatica Acute, Lumbar Spinal Stenosis	Primus Pharmaceuticals	Metaxalone 640 mg Oral Tablet	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-15 in 11d ESTIMATED	READOUT Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Gla Phase 2 · Glaucoma, Open-Angle, Ocular Hypertension	PolyActiva Pty Ltd	PA5108 Ocular Implant low dose, PA5108 O	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-16 in 12d ESTIMATED	READOUT A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Gener Phase 2/3 · Generalized Myasthenia Gravis	UCB Biopharma SRL	Zilucoplan	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-17 in 13d ESTIMATED	READOUT AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 Phase 2 · Gastric Cancer, Gastroesophageal Junction Cancer	AZN ASTRAZENECA PLC	AZD0901, 5-Fluorouracil, Leucovorin, l-l	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-17 in 13d ESTIMATED	READOUT A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemo Phase 4 · Haemophilia A (Moderate or Severe), Hemophilia, Classic	Swedish Orphan Biovitrum	Efanesoctocog alfa	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-18 in 14d ESTIMATED	READOUT Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polym Phase 2/3 · Small Cell Lung Cancer	Han Xu, M.D., Ph.D., FAPCR, Medica	ETOPOSIDE - Usual, ETOPOSIDE - Study	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-18 in 14d ESTIMATED	READOUT Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucl Phase 2/3 · Prostate Cancer	Han Xu, M.D., Ph.D., FAPCR, Sponso	Abiraterone - Usual, Abiraterone - Study	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-18 in 14d ESTIMATED	READOUT A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Ac Phase 3 · Sjögren's Syndrome	BMY BRISTOL MYERS SQUIBB CO	Deucravacitinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-18 in 14d ESTIMATED	READOUT Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymo Phase 2/3 · ALK-Positive Non-Small Cell Lung Cancer (NSCLC)	Medicine Invention Design, Inc	ALECENSA - alectinib hydrochloride capsu	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-18 in 14d ESTIMATED	READOUT A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular D Phase 2 · Duchenne Muscular Dystrophy	Hoffmann-La Roche	Satralizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-18 in 14d ESTIMATED	READOUT An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer Phase 2 · Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)	ToLymph Inc.	SMS001	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-19 in 15d ESTIMATED	READOUT A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Par Phase 4 · Severe Hemophilia A, Moderate Hemophilia A	Hoffmann-La Roche	Emicizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-19 in 15d ESTIMATED	READOUT A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participant Phase 2 · Alzheimer's Disease	Hoffmann-La Roche	RO7269162	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-19 in 15d ESTIMATED	READOUT A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatiti Phase 2 · Dermatitis, Atopic	Janssen Research & Development, LL	JNJ-95597528	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-19 in 15d CONFIRMED	ADCOM Microbiology Devices Panel of the Medical Devices Advisory Committee Microbiology Devices Panel of the Medical Devices Advisory Committee	Microbiology Devices Panel of the	FDORA	Federal Register (FDA notice) ↗ ✓ Source-checked 2026-11-04 Scheduled FDA meeting date
2026-11-20 in 16d ESTIMATED	READOUT Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With Phase 3 · Endometrial Neoplasms	Merck Sharp & Dohme LLC	Pembrolizumab, Carboplatin, Paclitaxel,	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-20 in 16d ESTIMATED	READOUT A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participant Phase 2 · Moderate to Severe Asthma	INCY INCYTE CORP	povorcitinib, ICS-LABA	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-20 in 16d ESTIMATED	READOUT Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-admi Phase 2 · Obesity	SKYE Skye Bioscience, Inc.	Nimacimab injection, Nimacimab placebo i	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-23 in 19d ESTIMATED	READOUT A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) V Phase 2 · Neoplasms, Colon	GlaxoSmithKline	Dostarlimab, CAPEOX	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-23 in 19d ESTIMATED	READOUT A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to He Phase 3 · Chickenpox	GlaxoSmithKline	Investigational varicella vaccine, Marke	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-24 in 20d ESTIMATED	READOUT Avelumab Program Rollover Study Phase 3 · Solid Tumors	EMD Serono Research & Development	Avelumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-24 in 20d ESTIMATED	READOUT Study of AZD0754 in Participants With Metastatic Prostate Cancer Phase 1/2 · Metastatic Prostate Cancer	AZN ASTRAZENECA PLC	AZD0754, AZD2287	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-24 in 20d ESTIMATED	READOUT A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer Phase 3 · Alzheimer Disease	Karuna Therapeutics, Inc., a Brist	KarXT	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-24 in 20d ESTIMATED	READOUT A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart F Phase 2 · Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction	TECX Tectonic Therapeutic, Inc.	TX000045- Dose A, TX000045- Dose B	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-26 in 22d ESTIMATED	READOUT A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Phase 3 · Neoplasms	Tesaro, Inc.	Dostarlimab, Carboplatin, Paclitaxel, Ni	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-26 in 22d ESTIMATED	READOUT Study of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and Phase 4 · COVID-19	SNY Sanofi	Omicron Subvariant-Based SARS-CoV-2 Reco	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-28 in 24d ESTIMATED	READOUT A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Phase 2 · Parkinson's Disease (PD)	TrueBinding, Inc.	TB006	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-28 in 24d ESTIMATED	READOUT A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric P Phase 3 · Yellow Fever Immunization	SNY Sanofi	Yellow fever vaccine (live), Yellow feve	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-29 in 25d ESTIMATED	READOUT A Study to Learn About the Study Medicine Called Rimegepant in Women When Used f Phase 3 · Menstrual Migraine	PFE PFIZER INC	Rimegepant, Rimegepant	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-30 in 26d ESTIMATED	READOUT Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutat Phase 1/2 · Glioblastoma Multiforme	NTHI NEONC TECHNOLOGIES HOLDINGS,	Perillyl alcohol	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-30 in 26d ESTIMATED	READOUT A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-L Phase 3 · Cancer	Hoffmann-La Roche	Atezolizumab, Bevacizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-30 in 26d ESTIMATED	READOUT Microdystrophin Gene Transfer Study in Adolescents and Children With DMD Phase 1/2 · Duchenne Muscular Dystrophy	SLDB Solid Biosciences Inc.	SGT-001	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-30 in 26d ESTIMATED	READOUT A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety Phase 1/2 · Multiple Myeloma	Celgene	CC-92480, Bortezomib, Dexamethasone, Dar	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-30 in 26d ESTIMATED	READOUT A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Phase 2 · Non-small Cell Lung Cancer	Genentech, Inc.	Alectinib, Entrectinib, Vemurafenib, Cob	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-30 in 26d ESTIMATED	READOUT A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MT Phase 1/2 · Advanced MTAP-null Solid Tumors	AMGN AMGEN INC	Anvumetostat, Docetaxel, Comparator Anvu	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-30 in 26d ESTIMATED	READOUT A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage D Phase 1/2 · Glycogen Storage Disease	ModernaTX, Inc.	mRNA-3745	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-30 in 26d ESTIMATED	READOUT Pediatric Patients Aged 4 to 11 Years With APDS Phase 3 · APDS	Pharming Technologies B.V.	Leniolisib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-30 in 26d ESTIMATED	READOUT A Study to Evaluate Efficacy and Safety of AVTX-803 in Patients With Leukocyte A Phase 3 · Leukocyte Adhesion Deficiency	AUG Therapeutics	AVTX-803 (L-Fucose)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-30 in 26d ESTIMATED	READOUT ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC Phase 1/2 · Metastatic Castration-resistant Prostate Cancer	OncoC4, Inc.	ONC-392 low, ONC-392 high, lutetium Lu 1	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-30 in 26d ESTIMATED	READOUT AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Phase 1/2 · Mesial Temporal Lobe Epilepsy	UniQure Biopharma B.V.	AAV9-hSyn1-miGRIK2	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-30 in 26d ESTIMATED	READOUT Suprachoroidal Administration in Subjects With Metastases to the Choroid Phase 2 · Eye Cancer, Primary Cancer	AURA Aura Biosciences, Inc.	AU-011, SCS Microinjector, Laser	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-30 in 26d ESTIMATED	READOUT A Study of TAK-360 in Adults With Idiopathic Hypersomnia Phase 2 · Idiopathic Hypersomnia	TAK TAKEDA PHARMACEUTICAL CO LTD	TAK-360	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-30 in 26d ESTIMATED	READOUT A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) Phase 2 · Narcolepsy Type 2	TAK TAKEDA PHARMACEUTICAL CO LTD	TAK-360	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-30 in 26d ESTIMATED	READOUT A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metast Phase 3 · Breast Cancer	InventisBio Co., Ltd	D-0502, Fulvestrant	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-30 in 26d ESTIMATED	READOUT A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12 Phase 1/2 · KRAS G12D Mutation, Advanced Solid Cancer	ARVN ARVINAS, INC.	ARV-806	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-30 in 26d ESTIMATED	READOUT Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production C Phase 2 · Monkeypox (Mpox)	Bavarian Nordic	Jynneos, MVA-BN (Quail)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-30 in 26d ESTIMATED	READOUT Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Pha Phase 3 · Immune Thrombocytopenia	SNY Sanofi	rilzabrutinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-30 in 26d ESTIMATED	READOUT Phase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis K Phase 3 · Osteoarthritis Knee Pain	Saol Therapeutics Inc	SL1002, Normal Saline	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-30 in 26d ESTIMATED	READOUT Investigating Ovulation Inhibition for Use as a Contraceptive Phase 2 · Contraception	Mylan Pharmaceuticals Inc	MR-130A-01 contraceptive transdermal pat	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-30 in 26d ESTIMATED	READOUT A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE Phase 2 · Obesity and Cardiovascular Risk	BIOA BioAge Labs, Inc.	Oral BGE-102, Oral Placebo Matching BGE-	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-30 in 26d ESTIMATED	READOUT Study to Assess Safety and Tolerability of KarXT With Administration of Antiemet Phase 4 · Healthy Volunteers	Karuna Therapeutics, Inc., a Brist	KarXT, Trimethobenzamide, Ondansetron, M	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change